APRE
Aprea TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Composite grade F from latest DB weights. Momentum 10.4 / Value 58.4
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
10
Value
58
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $5.33
Why
Momentum10 · Δ7d -
Value58 · Δ7d -0.0
SentimentN/A · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
10
52% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
58
48% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.0
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 10.4 / Value 58.4
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$9.46M
Beta
1.48
Shares Out
6.99M
P/E (TTM) · Derived
-0.6
P/S (TTM)
12.58
P/FCF (TTM) · Derived
-0.61
Rev YoY
-99.5%
EPS YoY
+26.8%
Gross Margin
-
Op Margin
-2829.9%
Net Debt
-
Current Ratio
5.20
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology